Pimavanserin tartrate Drug Asset Due Diligence Report 2026

This Pimavanserin tartrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

105

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Pimavanserin tartrate can convert its Small molecule drug profile and 5-HT2A receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pimavanserin tartrate (query alias: pimavanserin)
Modality / target	Small molecule drug; 5-HT2A receptor; 5-HT2A receptor inverse agonists
Highest global status	Approved
Originator	ACADIA Pharmaceuticals, Inc.
Active developers	ACADIA Pharmaceuticals, Inc., Tasly Pharmaceutical Group Co., Ltd., Tianjin Tasly Shengte Pharmaceutical Co. Ltd.

The MCP disease footprint includes Delusions, Hallucinations, Parkinson Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20261709	Phase 3	进行中（招募中）	188	Not disclosed
CTR20252689	Phase 3	进行中（招募中）	9	Not disclosed
NCT07610135	Phase 1/2	Not yet recruiting	20	Persisting Effects Questionnaire (PEQ) score

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Pimavanserin for Irritability in Children and Adolescents With Autism Spectrum Disorder: Phase 2 Randomized Trial

Phase 2; n=216; evaluation: Negative. Reported fields: ABC-I subscale score(6-week) = -11.2 Point ( -13.3 to -9.1); ABC-I subscale score(6-week) = -11.2 Point ( -13.3 to -9.0); ABC-I subscale score(6-week) = -9.6 Point ( -11.7 to -7.5)

A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (ASD)

Phase 2/3; n=209; evaluation: not stated. Reported fields: TEAE = 132 Participants ; -; -

Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study

Phase 3; n=46; evaluation: Positive. Reported fields: Psychosis relapse risk: HR = 0.031(95.0% CI, 0.01 - 0.103), P-Value = < 0.0001; Psychosis relapse risk: HR = 0.031(95.0% CI, 0.01 - 0.103), P-Value = < 0.0001

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pimavanserin tartrate addresses Delusions, Hallucinations, Parkinson Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 105 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: 5-HT2A receptor records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-30	Azurity Pharmaceuticals Expands Portfolio with CONTRAVE® and Related Assets	Approved	Financial terms not disclosed
2026-04-21	Tortugas Neuroscience licensed TRTL-107 and TRTL-913 from China’s Hansoh	Phase 2	Financial terms not disclosed
2026-02-23	Nippon Shinyaku : Transfer of Marketing Authorization for Epileptic Seizures treatment FINTEPLA® Oral Solution 2.2 mg/mL	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Orally disintegrating tablet of pimavanserin or salt thereof and preparation method of orally disintegrating tablet”. The milestone feed surfaced a patent-application signal described as “Synthesis method of pimavanserin tartrate”. The milestone feed surfaced a patent-application signal described as “Methods of treating 5HT2a receptor-mediated conditions”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO